Abstract:Background: Atopic dermatitis (AD) in high-burden skin areas such as the head-and-neck, the hands, and the genitals is associated with a high disease burden and impaired quality-of-life.
Objective: We investigated the prevalence of AD in high-burden skin areas, clinical and demographic characteristics, and association with disease severity in adults with AD.
Methods: A cross-sectional survey was sent to 16,718 adults seen with AD (ICD-10, L20.x) at a Danish hospital. Severity was assessed with the Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD).
Results: 7049 completed the survey (42.2% response), and 6716 who reported anatomical site of AD were included. The point prevalence of hand eczema (HE), head-and-neck dermatitis (HND), and genital eczema (GE) increased with AD severity and was 68.7%, 60.0%, and 5.9% in moderate, and 81.7%, 75.6%, and 14.1% in severe AD (P < 0.001). HND and HE patients were primarily women with childhood-onset and more severe AD. GE patients tended to be male, had severe AD, had more atopic comorbidities, and had higher corticosteroid and antibiotic use.
Conclusions: AD in high-burden areas is common in adult Danes with AD and characterized by more severe AD and specific patient characteristics. This subgroup warrants recognition as difficult-to-treat, requiring close monitoring and earlier use of advanced systemic therapy.
Ramírez-MarínHA, SilverbergJI. Differences between pediatric and adult atopic dermatitis. Pediatr Dermatol. 2022; 39(3):345–353; doi: 10.1111/pde.14971
3.
GernerT, RinnovMR, HallingAS, et al.Differences in occurrence, risk factors and severity of early-onset atopic dermatitis among preterm and term children. Acta Derm Venereol. 2022; 102:adv00737; doi: 10.2340/actadv.v102.575
4.
PolaskeyMT, BendelowA, MukherjiJ, et al.Facial atopic dermatitis is associated with sensitization to cow’s milk, egg whites, and peanuts in children under 36 months. Pediatr Dermatol. 2023; 40(3):497–499; doi: 10.1111/pde.15326
5.
HalkjaerLB, LolandL, BuchvaldFF, et al.Development of atopic dermatitis during the first 3 years of life: The Copenhagen prospective study on asthma in childhood cohort study in high-risk children. Arch Dermatol. 2006; 142(5):561–566; doi: 10.1001/archderm.142.5.561
6.
RønnstadATM, ThomsenSF, ThyssenJP, et al.The burden of head-and-neck dermatitis in adults with atopic dermatitis and its association with asthma, rhinitis, and disease severity. J Am Acad Dermatol. 2023:S0190; doi: 10.1016/j.jaad.2023.10.042
7.
Silvestre SalvadorJF, Romero-PérezD, Encabo-DuránB. Atopic dermatitis in adults: A diagnostic challenge. J Investig Allergol Clin Immunol. 2017; 27(2):78–88; doi: 10.18176/jiaci.0138
8.
RuffSMD, EngebretsenKA, ZachariaeC, et al.The association between atopic dermatitis and hand eczema: A systematic review and meta-analysis. Br J Dermatol. 2018; 178(4):879–888; doi: 10.1111/bjd.16147
9.
SimpsonEL, ThompsonMM, HanifinJM. Prevalence and morphology of hand eczema in patients with atopic dermatitis. Dermatitis. 2006; 17(3):123–127; doi: 10.2310/6620.2006.06005
10.
SilverbergJI, SimpsonB, AbuabaraK, et al.; TARGET-DERM Investigators. Prevalence and burden of atopic dermatitis involving the head, neck, face, and hand: A cross sectional study from the TARGET-DERM AD cohort. J Am Acad Dermatol. 2023; 89(3):519–528; doi: 10.1016/j.jaad.2023.04.052
11.
SilverbergJI, MargolisDJ, BoguniewiczM, et al.Distribution of atopic dermatitis lesions in United States adults. J Eur Acad Dermatol Venereol. 2019; 33(7):1341–1348; doi: 10.1111/jdv.15574
12.
WooYR, HanY, LeeJH, et al.Real-world prevalence and burden of genital eczema in atopic dermatitis: A multicenter questionnaire-based study. J Dermatol. 2021; 48(5):625–632; doi: 10.1111/1346-8138.15817
13.
RønnstadATM, Halling-OvergaardAS, HamannCR, et al.Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: A systematic review and meta-analysis. J Am Acad Dermatol. 2018; 79(3):448–456.e30; doi: 10.1016/j.jaad.2018.03.017
14.
BirdiG, CookeR, KnibbRC. Impact of atopic dermatitis on quality of life in adults: A systematic review and meta-analysis. Int J Dermatol. 2020; 59(4):e75–e91; doi: 10.1111/ijd.14763
15.
EgebergA, ThyssenJP. Factors associated with patient-reported importance of skin clearance among adults with psoriasis and atopic dermatitis. J Am Acad Dermatol. 2019; 81(4):943–949; doi: 10.1016/j.jaad.2019.06.018
16.
LioPA, WollenbergA, ThyssenJP, et al.Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020; 19(10):943–948; doi: 10.36849/JDD.2020.5422
17.
KaundinyaT, RakitaU, SilverbergJI. Prevalence, predictors, and longitudinal course of sexual dysfunction in adults with atopic dermatitis. Dermatitis. 2023; 34(3):233–240; doi: 10.1097/DER.0000000000000938
18.
WollenbergA, KinbergerM, ArentsB, et al.European Guideline (EuroGuiDerm) on atopic eczema: Living update. J Eur Acad Dermatol Venereol. 2025; 39(9):1537–1566; doi: 10.1111/jdv.20639
19.
ElmetsCA, KormanNJ, PraterEF, et al.Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021; 84(2):432–470; doi: 10.1016/j.jaad.2020.07.087
20.
SeegräberM, SrourJ, WalterA, et al.Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018; 11(5):467–474; doi: 10.1080/17512433.2018.1449642
21.
WollenbergA, WeidingerS, WormM, et al.Tralokinumab bei atopischer Dermatitis. J Deutsche Derma Gesell. 2021; 19(10):1435–1442; doi: 10.1111/ddg.14545_g
22.
LohTY, HsiaoJL, ShiVY. Therapeutic potential of lebrikizumab in the treatment of atopic dermatitis. J Asthma Allergy. 2020; 13:109–114; doi: 10.2147/JAA.S211032
23.
BraithwaiteIE, CaiF, TomJA, et al.Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial. J Allergy Clin Immunol. 2021; 148(3):783–789; doi: 10.1016/j.jaci.2021.02.042
24.
GeorasSN, DonohueP, ConnollyM, et al.JAK inhibitors for asthma. J Allergy Clin Immunol. 2021; 148(4):953–963; doi: 10.1016/j.jaci.2021.08.013
25.
ChiricozziA, GoriN, Di NardoL, et al.Therapeutic impact and management of persistent head and neck atopic dermatitis in dupilumab-treated patients. Dermatology. 2022; 238(4):717–724; doi: 10.1159/000519361
26.
GoriN, IppolitiE, PerisK, et al.Head and neck atopic dermatitis: Still a challenging manifestation in the biologic era. Expert Opin Biol Ther. 2023; 23(7):575–577; doi: 10.1080/14712598.2023.2224499
27.
VittrupI, KroghNS, LarsenHHP, et al.A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: Ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023; 37(5):1046–1055; doi: 10.1111/jdv.18849
28.
ChovatiyaR, RiberoS, WollenbergA, et al.Long-term disease control and minimal disease activity of head and neck atopic dermatitis in patients treated with tralokinumab up to 4 years. Am J Clin Dermatol. 2025; 26(4):587–601; doi: 10.1007/s40257-025-00931-1
29.
Navarro-TriviñoFJ, Salazar-NievasM, Sanz-CabanillasJL, et al.Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients. Australas J Dermatol. 2024; 65(3):260–265; doi: 10.1111/ajd.14264
30.
SchlösserAR, ShareefM, OlydamJ, et al.Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice. Clin Exp Dermatol. 2023; 48(5):510–517; doi: 10.1093/ced/llad038
31.
WeisshaarE. Chronic hand eczema. Am J Clin Dermatol. 2024; 25(6):909–926; doi: 10.1007/s40257-024-00890-z
32.
KamphuisE, BoesjesCM, LomanL, et al.Real-world experience of abrocitinib treatment in patients with atopic dermatitis and hand eczema: Up to 28-week results from the bioday registry. Acta Derm Venereol. 2024; 104:adv19454; doi: 10.2340/actadv.v104.19454
33.
SimpsonEL, SilverbergJI, WormM, et al.Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2024; 90(6):1190–1199; doi: 10.1016/j.jaad.2023.12.066
34.
SimpsonEL, RahawiK, HuX, et al.Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials. J Eur Acad Dermatol Venereol. 2023; 37(9):1863–1870; doi: 10.1111/jdv.19194
LicataG, GambardellaA, TancrediV, et al.Face atopic dermatitis resistant to dupilumab: A case series of three patients successfully treated with upadacitinib. J Eur Acad Dermatol Venereol. 2022; 36(2):e150–e152; doi: 10.1111/jdv.17705
37.
PariserD. Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: Focus on percutaneous absorption. Am J Ther. 2009; 16(3):264–273; doi: 10.1097/MJT.0b013e31818a975c
38.
PaolinoG, NarcisiA, CarugnoA, et al.Successful use of tralokinumab for the treatment of atopic dermatitis on the genitals. J Dermatolog Treat. 2024; 35(1):2351489; doi: 10.1080/09546634.2024.2351489
39.
PaolinoG, SernicolaA, Di NicolaMR, et al.Successful use of dupilumab for the treatment of atopic dermatitis on the genitals, a neglected anatomical site. Clin Exp Dermatol. 2022; 47(1):176–178; doi: 10.1111/ced.14894
40.
GoriN, GalluzzoM, ChiricozziA, et al.Evaluation of upadacitinib efficacy in the treatment of atopic dermatitis of sensitive areas. Dermatology. 2025; 241(3):223–229; doi: 10.1159/000545227
41.
StalderJF, BarbarotS, WollenbergA, et al.; PO-SCORAD Investigators Group. Patient-Oriented SCORAD (PO-SCORAD): A new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011; 66(8):1114–1121; doi: 10.1111/j.1398-9995.2011.02577.x
42.
WilliamsHC, SchmittJ, ThomasKS, et al.; HOME Initiative. The HOME core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022; 149(6):1899–1911; doi: 10.1016/j.jaci.2022.03.017
43.
RuzickaT, LyndeCW, JemecGBE, et al.Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: Results of a randomized, double-blind, placebo-controlled, multicentre trial. Br J Dermatol. 2008; 158(4):808–817; doi: 10.1111/j.1365-2133.2008.08487.x
44.
ChovatiyaR, SilverbergJI. Evaluating the longitudinal course of atopic dermatitis: Implications for clinical practice. Am J Clin Dermatol. 2022; 23(4):459–468; doi: 10.1007/s40257-022-00697-w
45.
AndersenYMF, EgebergA, SkovL, et al.Demographics, healthcare utilization and drug use in children and adults with atopic dermatitis in Denmark: A population-based cross-sectional study. J Eur Acad Dermatol Venereol. 2019; 33(6):1133–1142; doi: 10.1111/jdv.15424
46.
BoyleJ, BermanL, DaytonJ, et al.Physical measures and biomarker collection in health surveys: Propensity to participate. Res Social Adm Pharm. 2021; 17(5):921–929; doi: 10.1016/j.sapharm.2020.07.025
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
